Please assess the completion status of the following clinical trial:

Trial Title: Second-line Switch to Dolutegravir Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able and willing to understand and comply with the protocol requirements, instructions and restrictions~* Able and willing to give informed consent~* Age 18 years or above~* Documented HIV-1 infection as confirmed by HIV-antibody testing as per the Kenya National Guidelines~* Has been receiving a second-line ARV regimen containing a PI/r (DRV/r, ATV/r or LPV/r) and 2 NRTIs for at least 24 weeks~* Documented HIV-1 RNA viral load \< 50 copies/ml at least 12 weeks prior to enrollment and no viral rebound between the first viral load \< 50 copies/ml and the screening viral load~* HIV-1 RNA viral load \< 50 copies/ml at screening (within 28 days prior to enrollment)~* If female and of childbearing potential, is using effective contraception and is willing to continue using effective contraception throughout the study period (as defined in Appendix 5). Note: Non-childbearing potential is defined as either post-menopausal (12 months of spontaneous amenorrhoea and age of 45 years or above) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy~Exclusion Criteria:~* Any prior use of integrase inhibitor~* Documented HIV-2 infection~* Using any concomitant therapy disallowed as per the reference safety information and product labelling for the study drugs~* Has AST and/or ALT at least 5-times greater than the upper limit of normal in conjunction with hepatitis B virus infection (HBV) or hepatitis C virus infection (HCV). Note: patients can enter the study with chronic HBV or HCV if AST and ALT are less than 5-times greater than the upper limit of normal and, in the investigators opinion, their medical status will not interfere with assessments or completion of the study~* Is both HBsAg positive and has a CrCl below 50 ml/min (as estimated using the Cockcroft-Gault estimate for glomerular filtration rate)~* Advanced renal insufficiency requiring dialysis~* If female, currently pregnant or breastfeeding, or intending to become pregnant during the study period~* Documented opportunistic infection within 4 weeks prior to the study enrolment~* Investigator opinion that the patient should switch from PI/r to DTG immediately for clinical reasons (including Grade 3 or 4 lipid abnormalities at screening or enrollment)~* Any condition (including illicit drug use or alcohol abuse) or laboratory results which, in the investigator's opinion, interfere with assessments or completion of the study~* History or presence of allergy to the study drugs or their components

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dolutegravir (Type: EXPERIMENTAL): Participants in this arm will have a switch from a protease inhibitor based second line regimen to Dolutegravir maintaining the same NRTI backbone
- Protease Inhibitor (Type: ACTIVE_COMPARATOR): Participants in this arm will be maintained on their protease inhibitor based second line regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).